Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Short-term Investments (2016 - 2025)

Historic Short-term Investments for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $37.0 million.

  • UroGen Pharma's Short-term Investments fell 7032.38% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 7032.38%. This contributed to the annual value of $64.7 million for FY2024, which is 5416.77% up from last year.
  • As of Q3 2025, UroGen Pharma's Short-term Investments stood at $37.0 million, which was down 7032.38% from $64.0 million recorded in Q2 2025.
  • UroGen Pharma's Short-term Investments' 5-year high stood at $124.7 million during Q3 2024, with a 5-year trough of $21.1 million in Q2 2024.
  • For the 5-year period, UroGen Pharma's Short-term Investments averaged around $48.7 million, with its median value being $42.0 million (2023).
  • As far as peak fluctuations go, UroGen Pharma's Short-term Investments surged by 34340.54% in 2024, and later plummeted by 7032.38% in 2025.
  • Over the past 5 years, UroGen Pharma's Short-term Investments (Quarter) stood at $44.8 million in 2021, then decreased by 0.5% to $44.6 million in 2022, then dropped by 5.81% to $42.0 million in 2023, then skyrocketed by 54.17% to $64.7 million in 2024, then plummeted by 42.82% to $37.0 million in 2025.
  • Its Short-term Investments stands at $37.0 million for Q3 2025, versus $64.0 million for Q2 2025 and $91.9 million for Q1 2025.